The makings of a tumor rejection antigen

Immunity

Volumn 11, Issue 3, 1999, Pages 263-270

  Gilboa, Eli ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR REJECTION ANTIGEN;

ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CYTOTOXIC T LYMPHOCYTE; IMMUNOGENICITY; IMMUNOREGULATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION;

EID: 0033198562     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(00)80101-6     Document Type: Review

References (81)

1. Alexander-Miller, M.A., Leggatt, G.R., and Berzofsky, J.A. (1996a). Selective expansion of high or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93, 4102-4107.
2. Alexander-Miller, M.A., Leggatt, G.R., Sarin, A., and Berzofsky, J.A. (1996b). Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184, 485-492.
3. Anichini, A., Mortarini, R., Maccalli, C., Squarcina, P., Fleischhauer, K., Mascheroni, L., and, Parmiani. G. (1996). Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J. Immunol. 156, 208-217.
4. Ashley, D.M., Faiola, B., Nair, S., Hale, L.P., Bigner, D.D., and Gilboa, E. (1997). Bone marrow-generated dendritic cell pulsed with tumor extracts or tumor RNA induce anti-tumor immunity against central nervous system tumors. J. Exp. Med. 186, 1177-1182.
5. Boczkowski, D., Nair, S.K, Snyder, D., and Gilboa, E. (1996). Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465-472.
6. Boon, T., and van der Bruggen, P. (1996). Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725-729.
7. Brandle, D., Bilsborough, J., Rülicke, T., Uyttenhove, C., Boon, T., and Van den Eynde, B.J. (1998). The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur. J. Immunol. 28, 4010-4019.
8. Busch, D.H., and Pamer, E.G. (1998). MHC class I/peptide stability, implications for immunodominance, in vitro proliferation, and diversity of responding CTL. J. Immunol. 160, 4441-4448.
9. β T cell receptor repertoires against hen egg white lysozyme (HEL) in non-transgenic versus HEL transgenic mice. J. Exp. Med. 180, 861-872.
10. Coggin, J.H. (1989). Cross-reacting tumor associated transplantation antigen on primary 3-methylcholantrene-induced BALB/c sarcomas. Mol. Biother. 4, 223-228.
11. Cooper, S., Erickson, A.L., Adams, E.J., Kansopon, J., Weiner, A.J., Chien, D.Y., Houghton, M., Parham, P., and Walker, C.M. (1999). Analysis of a successful immune response against hepatitis C virus. Immunity 10, 439-449.
12. Cormier, J.N., Salgaller, M.L., Prevette, T., Barracchini, K.C., Rivoltini, L., Restifo, N.P., Rosenberg, S.A., and Marincola, F.M.. (1997). Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/melan A. Cancer J. 3, 37-44.
13. Coulie, P.G., Ikeda, H., Baurain, J.-F., and Chiari, R. (1999). Antitumor immunity at work in a melanoma patient. Adv. Cancer Res. 76, 213-242
14. - mutation. Proc. Natl. Acad. Sci. USA 85, 2274-2278.
15. Disis, M.L., and Cheever, M.A. (1996). Oncogenic proteins as tumor antigens. Curr. Opin. Immunol. 8, 637-642.
16. Dudley, M.E., and Roopenian, D.C. (1996). Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J. Exp. Med. 184, 441-447.
17. Fong, L., Ruegg, C.L., Brockstedt, D., Engleman, E.G., and, Laus, R. (1997). Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization. J. Immunol. 159, 3113-3117.
18. + T cells. Crit. Rev. Immunol. 18, 569-594.
19. Gallimore, A., Dumrese, T., Hengartner, H., Zinkernagel, R.M., and Rammensee, H.G. (1998). Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187, 1647-1657.
20. Garrido, F., Ruiz-Cabello, F., Cabrera, T., Perez-Villar, J.J., Lopez-Botet, M., Duggan-Keen, M., and Stern, P.L. (1997). Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol. Today 18, 89-95.
21. Gilboa, E., and Lyerly, H.K. (1994). Specific active immunotherapy of cancer using genetically modified tumor vaccines. In Biologic Therapy of Cancer Updates, S.A. Rosenberg, ed. (Philadelphia: J.B. Lippincott Company), pp. 1-16.
22. Gilboa, E., Nair, S.K., and Lyerly, H.K. (1998). Immunotherapy of cancer with dendritic-cell based vaccines. Cancer Immunol. Immunother. 46, 82-87
23. Hara, I., Takechi, Y., and Houghton, A.N. (1995). Implicating a role for immune recognition of self in tumor rejection, passive immunization against the Brown locus protein. J. Exp. Med. 182, 1609-1614.
24. Herlyn, D., and Birebent, B. (1999). Advances in cancer vaccine development. Ann. Med. 37, 66-78.
25. Hewitt, H., Blake, E., and Walder, A. (1976). A critique of the evidence for active host defense against cancer, based on person studies of 27 murine tumors of spontaneous origin. Cancer 33, 241-259.
26. Hicklin, D.J., Marincola, F.M., and Ferrone, S. (1999). HLA class I antigen downregulation in human cancers. Mol. Med. Today, in press.
27. Hu, J., Kindsvogel, W., Busby, S., Bailey, M.C., Shi, Y.-Y., and Greenberg, P.D. (1993). An evaluation of the potential to use tumor-associated antigens at targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J. Exp. Med. 177, 1681-1690.
28. Hurtado, J.C., Kim, Y.-J., and Kwon, B.S. (1997). Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J. Immunol. 158, 2600-2609.
29. Imro, M.A., Manici, S., Russo, V., Consogno, G., Bellone, M., Rugarli, C., Traversari, C., and Protti, M.P. (1999). Major histocompatibility class I restricted cytotoxic T cells specific for natural melanoma peptides recognize unidentified shared melanoma antigen(s). Cancer Res. 59, 2287-2291.
30. Jaeger, E., Bernhard, H., Romero, P., Ringhoffer, M., Arand, M., Karbach, J., Ilsemann, C., Hagedorn, M., and Knuth, A. (1996). Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo, implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer 66, 162-169.
31. + cytolytic T lymphocytes. J. Exp. Med. 183, 791-800.
32. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P.F., Rivoltini, L., Yannelli, J.R., Appella, E., and Rosenberg, S.A. (1994). Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180, 347-352.
33. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P.F., Sette, A., Appella, E., and Rosenberg, S.A. (1995). Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154, 3961-3968.
34. Klein, G., Sjogren, H.O., and Klein, E. (1960). Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20, 1561-1572.
35. Levitsky, H.I., Lazenby, A., Hayashi, R.J., and Pardoll, D.M. (1994). In vivo priming of two distinct antitumor effector populations. The role of MHC class I expression. J. Exp. Med. 179, 1215-1224.
36. Mandelboim, O., Berke, G., Fridkin, M., Feldman, M., Eisenstein, M., and Eisenbach, L. (1994). CTL induction by a tumor-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369, 67-71.
37. Mandelboim, O., Vadai, E., Fridkin, M., Katz-Hillel, A., Feldman, M., Berke, G., and Eisenbach, L. (1995). Regression of established murine carcinoma metastases following vaccination with tumor-associated antigen peptides. Nat. Med. 11, 1179-1183.
38. Mayordomo, J.I., Loftus, D.J., Sakamoto, H., De Cesare, C.M., Appasamy, P.M., Lotze, M.T., Storkus, W.J., Appella, E., and DeLeo, A.B. (1996). Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183, 1357-1365.
39. Melero, I., Singhal, M.C., McGowan, P., Haugen, H.S., Blake, J., Hellstrom, K.E., Yang, G., Clegg, C.H., and Chen, L. (1997). Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J. Virol. 71, 3998-4004.
40. Morgan, D.J., Kreuwel, H.T.C., Fleck, S., Levitsky, H.I., Pardoll, D.M., and Sherman, L.A. (1998). Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160, 643-651.
41. Naftziger, C., Takechi, Y., Kohda, H., Hara, I., Vijayasaradhi, S., and Houghton, A.N. (1996). Immune response to a differentiation antigen induced by altered antigen, a study of tumor rejection and autoimmunity. Proc. Natl. Acad. Sci. USA 93, 14809-14814.
42. Nair, S.K., Boczkowski, D., Morse, M., Cumming, R.I., Lyerly, H.K., and Gilboa, E. (1998). Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotech. 16, 364-369.
43. Nair, S.K., Hull, S., Coleman, D., Gilboa, E., Lyerly, H.K., and Morse, M.A. (1999). Induction of carcinoembryonic antigen (CEA)-specific CTL responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int. J. Cancer, in press.
44. Ochsenbein, A.F., Klenerman, P., Karrer, U., Ludewig, B., Pericin, M., Hengartner, H., and Zinkernagel, R.M. (1999). Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA 96, 2233-2238.
45. Oehen, S.U., Ohashi, P.S., Burki, K., Hengartner, H., Zinkernagel, R.M., and Aichele, P. (1994). Escape of thymocytes and mature T cells from clonal deletion due to limiting tolerogen expression levels. Cell. Immunol. 158, 342-352.
46. Old, L.J. (1981). Cancer immunology, the search for specificity - G.H.A. Lowes memorial lecture. Cancer Res. 41, 361-375.
47. Old, L.J., Boyse, E.A, Clarke, D.A., and Carswell, E.A. (1962). Antigenic properties of chemically induced tumors. Ann. N. Y. Acad. Sci. 101, 80-106.
48. + T lymphocytes. Proc. Natl. Acad. Sci. USA 96, 2982-2987.
49. Poindexter, N.J., Landon, C., Whiteley, P.J., and Kapp, J.A. (1992). Comparison of the T cell receptors on insulin-specific hybridomas from insulin transgenic and nontransgenic mice. J. Immunol. 149, 38-44.
50. Poplonski, L., Vukusic, B., Pawling, J., Clapoff, S., Roder, J., Hozumi, N., and Wither, J. (1996). Tolerance is overcome in beef insulin-transgenic mice by activation of low-avidity autoreactive T cells. Eur. J. Immunol. 26, 601-609.
51. Prehn, R.T., and Main, J.M. (1957). Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18, 769-778.
52. Prevost-Blondel, A., Zimmermann, C., Stemmer, C., Kulmburg, P., Rosenthal, F.M., and Pircher, H. (1998). Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol. 161, 2187-2194.
53. Qin, Z., Richter, G., Schüler, T., Ibe, S., Cao, X., and Blankenstein, T. (1998). B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 4, 627-630.
54. Ramarathinam, L., Sarma, S., Maric, M., Zhao, M., Yang, G., Chen, L., and Liu, Y. (1995). Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J. Immunol. 155, 5323-5329.
55. Rosato, A., Zambon, A., Milan, G., Ciminale, V., D'Agostino, D.M., Macino, B., Zanovello, P., and Collavo, D. (1997). CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A. Hum. Gene Ther. 8, 1451-1458.
56. Rosenberg, S.A. (1999). A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281-287.
57. Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J., Hwu, P., Marincola, F. M., Topolian, S.L., Restifo, N.P., Dudley, M.E., Schwartz, S.L., Spiess, P.J., et al. (1998). Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4, 321-327
58. Roth, J., Dittmer, D., Rea, D., Tartaglia, J., Paoletti, E., and Levine, A.J. (1996). p53 as a target for cancer vaccines. Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc. Natl. Acad. Sci. USA 93, 4781-4786.
59. Rowley, D.A., and Stach, R.M.. (1993). A first or dominant immunization. I. Suppression of simultaneous cytolytic T cell responses to unrelated alloantigens. J. Exp. Med. 178, 835-840.
60. Sahin, U., Türeci, Ö., and Pfreundschuh, M. (1997). Serological identification of human tumor antigens. Curr. Opin. Immunol. 9, 709-716.
61. Speiser, D.E., Kyburz, D., Stübi, U., Hengartner, H., and Zinkernagel, R.M. (1992). Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. J. Immunol. 149, 972-980.
62. Staveley-O'Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D., and Levitsky, H. (1998). Induction of antigen-specific T cell anergy, an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95, 1178-1183.
63. Syrengelas, A.D., and Levy, R. (1999). DNA vaccination against the idiotype of a murine B cell lymphoma: Mechanism of tumor protection. J. Immunol. 162, 4790-4795.
64. Tamura, Y., Peng, P., Liu, K., Daou, M., and Srivastava, P.K. (1997). Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278, 117-120.
65. Thompson, C.B., and Allison, J.P. (1997). The emerging role of CTLA-4 as an immune attenuator. Immunity 7, 445-450.
66. + T cells and their role in antitumor immune responses. J. Exp. Med. 189, 753-756.
67. Townsend, A., and Bodmer, H. (1989). Antigen recognition by class I-restricted T lymphocytes. Annu. Rev. Immunol. 7, 601-624.
68. Uyttenhove, C., Maryanski, J., and Boon, T. (1983). Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157, 1040-1052.
69. Van den Eynde, B., Lethé, B., Van Pel, A., De Plaen, E., and Boon, T. (1991). The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173, 1373-1384.
70. van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647.
71. van Parijs, L., and Abbas, A.K. (1996). Role of Fas-mediated cell death in the regulation of immune responses. Curr. Opin. Immunol. 8, 355-361.
72. van Pel, A., and Boon, T. (1982). Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc. Natl. Acad. Sci. USA 79, 4718-4722.
73. Vierboom, M.P.M., Nijman, H.W., Offringa, R., van der Voort, E.I.H., van Hall, T., van den Broek, L., Fleuren, G.J., Kenemans, P., Kast, W.M., and Melief, J.M (1997). Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186, 695-704.
74. von Herrath, M.G., Dockter, J., and Oldstone, M.B.A. (1994). How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity 1, 231-242.
75. Whiteside, T.L. (1998). Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects. Adv. Exp. Med. Biol. 451, 167-171.
76. Wick, M., Dubey, P., Koeppen, H., Siegel, C.T., Fields, P.E., Chen, L., Bluestone, J.A., and Schreiber, H. (1997). Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186, 229-238.
77. Yewdell, J.W., and Bennink, J.R. (1999). Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17, 51-88.
78. + T cells. Curr. Opin. Immunol. 10, 444-449.
79. Zeh, III, H.J., Perry-Lalley, D., Dudley, M.E., Rosenberg, S.A., and Yang, J.C. (1999). High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162, 989-994.
80. Zorn, E., and Hercend, T. (1999a). A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. Eur. J. Immunol. 29, 602-607.
81. Zorn, E., and Hercend, T. (1999b). A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur. J. Immunol. 29, 592-601.